Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1All patients in the study will be treated with ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
2Continued Ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
3OCR----[1] 13
4OCRELIZUMAB[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[3] 13, 46, 49
5Ocrelizumab (CinnaGen, Iran)[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
6Ocrelizumab (Roche, Switzerland)[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
7Ocrelizumab / rhuMAb 2H7[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 46
8Ocrelizumab 300 mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
9Ocrelizumab 300mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
10Ocrelizumab 300mg /10ml[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
11Ocrelizumab 300mg/10 ml[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
12Ocrelizumab 300mg/10ml[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
13Ocrelizumab 500mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 46
14Ocrelizumab 600 mg[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
15Ocrelizumab at home[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
16Ocrelizumab Dose 1[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
17Ocrelizumab Dose 2 and Dose 3[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
18Ocrelizumab IV[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
19Ocrelizumab SC[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
20Ocrelizumabu 200mg----[1] 46
21Ocrelizumabu 50mg----[1] 46
22OCREVUS[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
23Ocrevus 300 mg, solution à diluer pour perfusion[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
24Ocrrelizumab 300 mg----[1] 13
25Other: Observation of Ocrelizumab as Treatment in RRMS Patients[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
26Other: Ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13
27Ovine Corticotropin-Releasing Hormone (oCRH)[2] Corticorelin,
Corticotropin		[2] D00146 ,
D03905 		[3] CRHR1,
CRHR2,
MC2R 💬		[6] Aldosterone synthesis and secretion, Cortisol synthesis and secretion, Cushing syndrome, Long-term depression, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬[1] 75
28Short-course Ocrelizumab[1] Ocrelizumab[1] D05218 (Name: Ocrelizumab)[1] MS4A1 💬[1] Hematopoietic cell lineage 💬[1] 13